GSK invests another $77 million in Singapore antibiotic manufacturing plant

SINGAPORE - Pharmaceutical giant GlaxoSmithKline (GSK) will invest an additional £38 million (S$77 million) in its world-class antibiotic manufacturing plant at Quality Road in Singapore, building on its initial investment of $60 million committed in 2012.

The Quality Road plant is the company's sole production site for amoxicillin, an active compound used in the manufacture of antibiotics that are widely prescribed for the treatment of bacterial infections.

The new investment will be used to construct an additional downstream isolation facility for GSK's state-of-the-art enzymatic manufacturing facility at Quality Road.

This will increase production by 50 per cent and help the company meet the growing demand for antibiotics in emerging markets, it said in a statement released on Thursday.